BLAINTRAVENOUSINJECTABLE
Approved
Dec 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
ASPARLAS (calaspargase pegol) by R-Pharm US is l-asparaginase is an enzyme that catalyzes the conversion of the amino acid l-asparagine into aspartic acid and ammonia. First approved in 2018.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ASPARLAS (calaspargase pegol) is a pegylated L-asparaginase enzyme used to treat acute lymphoblastic leukemia (ALL) and T-cell lymphoblastic lymphoma by depleting plasma asparagine, starving leukemic cells that cannot synthesize their own asparagine. The pegylation extends half-life compared to native asparaginase, reducing dosing frequency. It is administered intravenously as part of multi-drug chemotherapy regimens.
Peak
Product is in peak commercial phase with R-Pharm US; competitive pressure of 30 suggests moderate market intensity and active commercial infrastructure.
Mechanism of Action
L-asparaginase is an enzyme that catalyzes the conversion of the amino acid L-asparagine into aspartic acid and ammonia. The pharmacological effect of ASPARLAS is thought to be based on the killing of leukemic cells due to depletion of plasma asparagine. Leukemic cells with low expression of…
Pharmacologic Class:
Asparagine-specific Enzyme
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
Started Aug 2022
15 enrolled
Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaStage II Pancreatic Cancer AJCC v8+4 more
SPARK-ALL: Calaspargase Pegol in Adults With ALL
Started Jul 2021
42 enrolled
Acute Lymphoblastic Leukemia
Worked on ASPARLAS at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.